RxDoctor Payments Data

Jennifer Binder

Family · Rockford, ILNPI 1295955284

Payments from drug & device makers

$318in general payments, 2019–2025

Across 11 payments — averaging $28.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$133
  • Lilly USA, LLC$74
  • Otsuka America Pharmaceutical, Inc.$50
  • Neurocrine Biosciences, Inc.$24
  • Acadia Pharmaceuticals Inc$19
  • Sunovion Pharmaceuticals Inc.$18

What the payments were for

  • Food & beverage$20866%
  • Education$10934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$318 in reported general payments places this provider in the 50th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$115,152
Medicare patients
141
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide105$107,970
JardianceEmpagliflozin159$66,587
GemtesaVibegron121$57,686
EliquisApixaban106$50,428
FarxigaDapagliflozin Propanediol100$44,960
XareltoRivaroxaban81$37,263
JanuviaSitagliptin Phosphate53$23,252
MyrbetriqMirabegron57$23,132
EntrestoSacubitril/Valsartan42$20,841
Breo ElliptaFluticasone/Vilanterol43$18,560
VraylarCariprazine Hcl15$17,588
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog119$15,722
RybelsusSemaglutide15$15,503
MounjaroTirzepatide12$11,905
OzempicSemaglutide11$11,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$74$119,875117 claims
Otsuka America Pharmaceutical, Inc.Rexulti$50$11,20716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,941 family providers in Illinois.

Other family in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →